Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prof William Pao to head Roche oncology unit

This article was originally published in Scrip

Executive Summary

Swiss pharma Roche has named professor of medicine at Vanderbilt University Medical Center, William Pao, global head of its oncology disease and translational unit – effective 1 May 2014. He will be based in Basel, Switzerland and will report to Dr John Reed global head of Roche Pharma Research and Early Development (pRED). Professor Pao is currently an advisor to the National Cancer Institute (NCI), American Association for Cancer Research (AACR), American Society for Clinical Oncology (ASCO), and other professional societies, while also serving on the editorial boards of several medical research journals including Cancer Research, Clinical Cancer Research, and Journal of Clinical Oncology. Furthermore, Professor Pao is a co-founder of MyCancerGenome, a web-based tool for clinical decision support to enable a genetically informed approach to cancer medicine. At Roche he will be responsible for leading the company's discovery, translational medicine and early development of innovative oncology medicines. 






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts